Newsroom | 18613 results

SAN DIEGO--(BUSINESS WIRE)--Allele Biotechnology & Pharmaceuticals, Inc. (Allele), a San Diego-based technology development and cell manufacturing company, today announced its participation in an up to $25.8 million research project with the University of California, San Diego, funded by the Advanced Research Projects Agency for Health (ARPA-H). The project’s goal is to develop a fully functional, patient-specific, 3D bioprinted liver for transplantation. This project is under ARPA-H’s Pers...

LOS ANGELES--(BUSINESS WIRE)--New physicians join HRC Fertility as California’s SB 729 drives increased access and demand for statewide IVF care....

SUNNYVALE, Calif.--(BUSINESS WIRE)--Integrated DNA Technologies announces a strategic move, expanding its San Francisco Bay Area presence to serve the vibrant biotechnology community....

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced an advancement in molecular residual disease (MRD)-based risk stratification that is expected to extend the company’s leadership in oncology. The new multi-modal model will integrate longitudinal ctDNA and clinical data with digital pathology imaging and tumor sequencing data, to enhance the Signatera™ MRD assessment. Signatera has transformed can...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced positive topline results from its first-in-human Phase 1 study of MAR002, a first-in-class allosteric monoclonal antibody targeting the growth hormone receptor (GHR) for the treatment of acromegaly. The company also highlighted key pipeline...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the early access launch of Real-Time Variant Tracker, a powerful new option added to its ultrasensitive NeXT Personal molecular residual disease (MRD) test designed to detect small traces of circulating tumor DNA (ctDNA) in the blood that represent residual or recurrent cancer. Clinicians using the NeXT Personal MRD test will now be able to opt-in for additional reporting...

SAN FRANCISCO & PALO ALTO, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Tahoe Therapeutics, Arc Institute, and Biohub announced a landmark initiative to generate the largest and most perturbation-rich single-cell dataset for virtual cell models. The effort is supported by a multi-institutional, multi-million dollar commitment by each of these groups, and represents the first collaboration of its kind at this scale. It extends the breakthroughs established with the perturbational datasets inc...

CAMBRIDGE, England--(BUSINESS WIRE)--OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5M seed funding round. The Company also announced the signing of a strategic agreement with o2h discovery, a preclinical Contract Research Organisation with an integrated drug discovery platform. The partnership aims to launch a collaborative drug discovery programme for OutSee’s lead target candid...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash equivalents, restricted cash and investments on hand as of December 31, 2025, as part of its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California. Financial Update* (preliminary and unaudited) Total net product revenu...

DUBLIN--(BUSINESS WIRE)--The "The Global Synthetic Biology & Biomanufacturing Market 2026-2036" has been added to ResearchAndMarkets.com's offering. The global synthetic biology and biomanufacturing market represents one of the most transformative sectors in the modern bioeconomy, positioned at the intersection of advanced biotechnology, computational biology, and sustainable manufacturing. This market encompasses the application of engineering principles to biology, enabling the design, co...